Anaplastic lymphoma kinase inhibitors for advanced non-small cell lung carcinoma

de Léséleuc L, MacDougall D
Record ID 32018002219
Original Title: ALK inhibitors for non-small cell lung cancer
Authors' objectives: The purpose of this CADTH Technology Review is to summarize the evidence findings regarding ALKi for NSCLC as identified by independent CADTH rapid health technology assessment (HTA) products, and to provide additional perspective, including an analysis of information gaps and further discussion on implications for decision-making, in order to assist the transition of current evidence into policy, practice, and future research.
Project Status: Completed
Year Published: 2019
English language abstract: An English language summary is available
Publication Type: Full HTA
Country: Canada
MeSH Terms
  • Lung Neoplasms
  • Carcinoma, Non-Small-Cell Lung
  • Crizotinib
  • Anaplastic Lymphoma Kinase
  • Protein Kinase Inhibitors
  • ALK inhibitors
  • Lung cancer
  • Anaplastic lymphoma kinase inhibitors
Organisation Name: Canadian Agency for Drugs and Technologies in Health
Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
Contact Email:

Canadian Agency for Drugs and Technologies in Health (CADTH)

This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.